Literature DB >> 23580787

Predictors of willingness to participate in window-of-opportunity breast trials.

Kari B Wisinski1, Adrienne Faerber, Stephanie Wagner, Thomas C Havighurst, Jane A McElroy, Kyungmann Kim, Howard H Bailey.   

Abstract

OBJECTIVE: We conducted a pilot survey to evaluate breast cancer patients' willingness to participate in a preoperative chemoprevention (ie, window-of-opportunity) study. Design A 27-question written survey was developed and administered to participants. Setting A breast cancer specialty clinic at the University of Wisconsin Hospital and Clinics. Participants 30 adult patients with newly diagnosed operable breast cancer participated after signing informed consent.
METHODS: A convenience sample of 30 participants was recruited from July 2005 through January 2006. Participants were administered the survey in clinic. Univariate ordinal logistic regression models were used to identify predictors of willingness to participate in window-of-opportunity trials.
RESULTS: Overall, 26.7% of respondents were willing to participate in a research trial between the time of breast cancer diagnosis and surgery. Univariate ordinal logistic regression models identified that women with a prior history of breast cancer (P=0.060), prior research participation (P=0.006), more education (P=0.034), and self-reported breast cancer knowledge (P=0.043) were more willing to participate. On average, women preferred to have surgery 7 days (range 1-14) after their diagnosis, but the actual average wait time between diagnostic biopsy and surgery was 37.5 days (standard deviation = 23.4 days).
CONCLUSION: There is ample time before breast surgery to conduct preoperative window-of-opportunity trials. Interventions aimed at expanding patients' breast cancer knowledge may improve accrual to window-of-opportunity studies.

Entities:  

Keywords:  Breast Cancer; Chemoprevention; Survey; Window-of-Opportunity

Mesh:

Year:  2013        PMID: 23580787      PMCID: PMC3788556          DOI: 10.3121/cmr.2013.1136

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  23 in total

Review 1.  Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

Authors:  B Glimelius; M Lahn
Journal:  Ann Oncol       Date:  2011-01-13       Impact factor: 32.976

2.  Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

Authors:  Sirwan Hadad; Takayuki Iwamoto; Lee Jordan; Colin Purdie; Susan Bray; Lee Baker; Gera Jellema; Steve Deharo; D Grahame Hardie; Lajos Pusztai; Stacy Moulder-Thompson; John A Dewar; Alastair M Thompson
Journal:  Breast Cancer Res Treat       Date:  2011-06-08       Impact factor: 4.872

3.  Ductal lavage for detection of cellular atypia in women at high risk for breast cancer.

Authors:  W C Dooley; B M Ljung; U Veronesi; M Cazzaniga; R M Elledge; J A O'Shaughnessy; H M Kuerer; D T Hung; S A Khan; R F Phillips; P A Ganz; D M Euhus; L J Esserman; B G Haffty; B L King; M C Kelley; M M Anderson; P J Schmit; R R Clark; F C Kass; B O Anderson; S L Troyan; R D Arias; J N Quiring; S M Love; D L Page; E B King
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

4.  A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.

Authors:  Edward Messing; Jason R Gee; Daniel R Saltzstein; KyungMann Kim; Anthony diSant'Agnese; Jill Kolesar; Linda Harris; Adrienne Faerber; Thomas Havighurst; Jay M Young; Mitchell Efros; Robert H Getzenberg; Marcia A Wheeler; Joseph Tangrea; Howard Parnes; Margaret House; J Erik Busby; Raymond Hohl; Howard Bailey
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-31

5.  Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide.

Authors:  E Singletary; R Lieberman; N Atkinson; N Sneige; A Sahin; S Tolley; M Colchin; T Bevers; C Stelling; B Fornage; H Fritsche; W Hittelman; G Kelloff; S M Lippman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-10       Impact factor: 4.254

6.  Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.

Authors:  S Eva Singletary; Edward N Atkinson; Ashraful Hoque; Nour Sneige; Ayse A Sahin; Herbert A Fritsche; Reuben Lotan; Tao Lu; Walter N Hittelman; Therese B Bevers; Carol B Stelling; Scott M Lippman
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

Review 7.  22. Diagnostic delays in breast cancer and impact on survival.

Authors:  A Kothari; I S Fentiman
Journal:  Int J Clin Pract       Date:  2003-04       Impact factor: 2.503

8.  A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.

Authors:  Andrea Decensi; Chris Robertson; Giuseppe Viale; Francesca Pigatto; Harriet Johansson; Elton R Kisanga; Paolo Veronesi; Rosalba Torrisi; Massimiliano Cazzaniga; Serena Mora; Maria T Sandri; Giuseppe Pelosi; Alberto Luini; Aron Goldhirsch; Ernst A Lien; Umberto Veronesi
Journal:  J Natl Cancer Inst       Date:  2003-06-04       Impact factor: 13.506

9.  Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Authors:  Bradley C Carthon; Jedd D Wolchok; Jianda Yuan; Ashish Kamat; Derek S Ng Tang; Jingjing Sun; Geoffrey Ku; Patricia Troncoso; Christopher J Logothetis; James P Allison; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

10.  Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.

Authors:  Lesley-Ann Martin; Giles L S Davies; Marion T Weigel; Nadine Betambeau; Margaret J Hills; Janine Salter; Geraldine Walsh; Roger A'Hern; Mitch Dowsett
Journal:  Breast Cancer Res Treat       Date:  2010-08-10       Impact factor: 4.872

View more
  3 in total

1.  Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker.

Authors:  Adam L Cohen; Leigh Neumayer; Ken Boucher; Rachel E Factor; Gajendra Shrestha; Mark Wade; John G Lamb; Kylee Arbogast; Stephen R Piccolo; Joanna Riegert; Matthias Schabel; Andrea H Bild; Theresa L Werner
Journal:  JCO Precis Oncol       Date:  2017-04-07

2.  Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.

Authors:  George W Sledge; Jennifer L Caswell-Jin; Divya A Parikh; Lisa Kody; Susie Brain; Diane Heditsian; Vivian Lee; Christina Curtis; Mardi R Karin; Irene L Wapnir; Manali I Patel
Journal:  Breast Cancer Res Treat       Date:  2022-05-11       Impact factor: 4.624

3.  Evaluating the feasibility of performing window of opportunity trials in breast cancer.

Authors:  Angel Arnaout; Susan Robertson; Iryna Kuchuk; Demetrios Simos; Gregory R Pond; Christina L Addison; Mehrzad Namazi; Mark Clemons
Journal:  Int J Surg Oncol       Date:  2015-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.